Ernexa Therapeutics Inc.

NASDAQ: ERNA · Real-Time Price · USD
1.27
0.09 (7.63%)
At close: Sep 16, 2025, 11:55 AM

Ernexa Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
582K 68K n/a n/a
Cost of Revenue
96K 236K 497K 459K
Gross Profit
486K -168K -497K -459K
Operating Income
-15.67M -21.14M -26.95M -27.43M
Interest Income
249K 138K n/a n/a
Pretax Income
-44.51M -21.67M -24.53M -122.3M
Net Income
-44.54M -21.67M -24.58M -122.31M
Selling & General & Admin
13.13M 14.59M 16.06M 14.72M
Research & Development
4.6M 5.92M 10.39M 12.71M
Other Expenses
-1.58M 461K n/a -459K
Operating Expenses
16.16M 20.97M 26.45M 26.97M
Interest Expense
6.75M 614K 30K 74K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
16.26M 21.2M 26.95M 27.43M
Income Tax Expense
30K -3K 45K 64K
Shares Outstanding (Basic)
28.4M 5.31M 3.05M 2.17M
Shares Outstanding (Diluted)
28.4M 5.31M 3.05M 2.17M
EPS (Basic)
-1.57 -4.08 -8.06 -56.61
EPS (Diluted)
-1.57 -4.08 -8.06 -56.61
EBITDA
-36.12M -19.93M -24.01M -121.95M
EBIT
-37.76M -21.06M -24.5M -122.41M
Depreciation & Amortization
1.64M 1.12M 497K 459K